Russell Investments Group Ltd. Has $1.37 Million Holdings in SciClone Pharmaceuticals, Inc. (SCLN)

Russell Investments Group Ltd. trimmed its position in shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 15.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 121,942 shares of the specialty pharmaceutical company’s stock after selling 22,043 shares during the quarter. Russell Investments Group Ltd. owned about 0.23% of SciClone Pharmaceuticals worth $1,366,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in SCLN. Profund Advisors LLC purchased a new stake in shares of SciClone Pharmaceuticals during the second quarter valued at about $113,000. Piedmont Investment Advisors LLC purchased a new stake in shares of SciClone Pharmaceuticals during the second quarter valued at about $123,000. Susquehanna International Group LLP purchased a new stake in shares of SciClone Pharmaceuticals during the second quarter valued at about $142,000. BNP Paribas Arbitrage SA lifted its position in shares of SciClone Pharmaceuticals by 54.0% during the second quarter. BNP Paribas Arbitrage SA now owns 16,140 shares of the specialty pharmaceutical company’s stock valued at $178,000 after buying an additional 5,658 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of SciClone Pharmaceuticals during the second quarter valued at about $195,000. 72.80% of the stock is owned by institutional investors and hedge funds.

Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) opened at $11.15 on Wednesday. SciClone Pharmaceuticals, Inc. has a 1 year low of $8.55 and a 1 year high of $11.43. The company has a market cap of $581.94 and a PE ratio of 12.97.

ILLEGAL ACTIVITY WARNING: “Russell Investments Group Ltd. Has $1.37 Million Holdings in SciClone Pharmaceuticals, Inc. (SCLN)” was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.com-unik.info/2017/12/27/russell-investments-group-ltd-has-1-37-million-holdings-in-sciclone-pharmaceuticals-inc-scln.html.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit